Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$18.78 USD
+0.46 (2.51%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $18.98 +0.20 (1.06%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.78 USD
+0.46 (2.51%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $18.98 +0.20 (1.06%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Zacks News
Jazz Pharma (JAZZ) Q4 Earnings & Sales Beat, Stock Up 8%
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) surpasses earnings and sales estimates in the fourth quarter and issues a solid outlook for 2019. Shares rise 8% in after-hours trading.
Is the Options Market Predicting a Spike in Corbus Pharmaceuticals (CRBP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Corbus Pharmaceuticals (CRBP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Corbus Pharmaceuticals (CRBP) closed at $7.64, marking a -0.52% move from the previous day.
Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) needs investors to pay close attention to the stock based on moves in the options market lately.
Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids
by Zacks Equity Research
CHMP gives positive opinion to Vertex's (VRTX) label expansion of Orkambi.
Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -23.81% and -34.12%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Corbus Pharmaceuticals (CRBP) in Focus: Stock Moves 6% Higher
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares rise 6% on the day, amid huge volumes.
Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Vertex Completes Enrollment in Triple Combination Studies
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) completes enrollment in two phase III studies evaluating VX-659 triple combination regimen in CF patients. Data is expected in the fourth quarter of 2018.
Vertex Inks Reimbursement Agreement for Orkambi in Australia
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) finalizes a reimbursement agreement with Australian government, which will improve the access to the drug.
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -5.00% and -55.05%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Vertex's Shares Rally as a Rival's CF Candidate Disappoints
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) stock rallies on disappointing study results on rival Galapagos' cystic fibrosis candidate. Vertex's third CF drug receives approval in Canada.
4 Best Marijuana Stocks to Play the Green Rush
by Zacks Equity Research
Given the increasing bullish environment, the movement to legalize marijuana has definitely picked up steam. Below are four cannabis-linked stocks that are poised to benefit from legalization.
Corbus Pharmaceuticals (CRBP) in Focus: Stock Moves 10% Higher
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) was a big mover last session, as the company saw its shares rise 10% on the day.
Aerie Pharmaceuticals (AERI) Surges: Stock Moves 16.2% Higher
by Zacks Equity Research
Aerie Pharmaceuticals (AERI) was a big mover last session, as the company saw its shares rise more than 16% on the day amid huge volumes.
Flexion Therapeutics (FLXN) in Focus: Stock Moves 10.4% Higher
by Zacks Equity Research
Flexion Therapeutics (FLXN) shares rose more than 10% in the last trading session, amid huge volumes.
Infinity Pharmaceuticals, Inc. (INFI) in Focus: Stock Moves 12% Higher
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) saw its shares rise nearly 12% on the day.
Collegium Pharmaceutical (COLL) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
Collegium Pharmaceutical (COLL) shares rose 6% in the last trading session, amid huge volumes.
Aldeyra Therapeutics (ALDX) Soars: Stock Adds 34.5% in Session
by Zacks Equity Research
Aldeyra Therapeutics (ALDX) saw a big move last session, as its shares jumped more than 34% on the day, amid huge volumes.
3 Reasons Momentum Stock Investors Will Love Corbus Pharmaceuticals Holdings (CRBP)
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.
Advanced Accelerator Applications (AAAP) in Focus: Stock Moves 7.5% Higher
by Zacks Equity Research
Advanced Accelerator Applications S.A. (AAAP) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
Surging Earnings Estimates Signal Good News for Corbus Pharmaceuticals (CRBP)
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.
Play the Marijuana Rush as First Marijuana-Focused ETF Launches
by Arpita Dutt
The medical marijuana industry has been gaining a lot of importance and attracting interest from investors over the last few quarters with companies like GW Pharma (GWPH) making headlines.
Corbus Concludes Phase II study of Cystic Fibrosis Candidate
by Zacks Equity Research
Corbus Pharmaceuticals Holdings, Inc. (CRBP), recently announced that it has concluded Phase II trial evaluating pipeline candidate, JBT-101 (resunab), for the treatment of cystic fibrosis (CF).